results in tyrosine phosphorylation of several cytosolic disruption of IRS-1 (Araki et al., 1994; Tamemoto et al., hypersecrete insulin. Only individuals in whom ␤ cell compensation is inadequate develop diabetes. The criti-1994), which causes growth retardation and mild insulin cal partnership between genetic determinants of insulin resistance but not frank diabetes because insulin secreaction and insulin secretion has previously been demontion increases to compensate for the resistance. Indeed, strated in transgenic mice with simultaneous disruption the relatively mild insulin resistance and residual ability of two separate genes, for example, IRS-1 impairing of insulin to partially stimulate glucose uptake in tissues insulin action and glucokinase impairing insulin secreof IRS-1 knockout mice (Araki et al., 1994; Tamemoto tion (Terauchi et al., 1997) . However, the current report et al., 1994) were important clues to the existence of gives substance to the speculation that defects in a other IRSs including IRS-2. In retrospect, differences in single gene product could impair both insulin action and the consequences of IRS-1 and IRS-2 disruption might secretion, thereby causing diabetes. be expected since, in spite of high homology of these Humans with Type 2 diabetes have reduced ␤ cell proteins, recent data demonstrate unique interactions mass compared to weight-matched nondiabetic subwith activated insulin receptors and different tyrosine jects (Kloppel et al., 1985) , consistent with the animal phosphorylation motifs in the COOH termini suggest data showing that failure of ␤ cell compensation is assounique signaling patterns (see references in Bernal et ciated with diabetes. Intense research has focused on al., 1998). Tissue distribution indicates that IRS-2 mRNA promoting islet cell growth and/or survival in models of is more abundant than IRS-1 in liver and pancreas (BerType 2 diabetes as well as in islet transplantation studies nal et al., 1998), although both are widely expressed and aimed at both Type 1 and 2 diabetes. Understanding the are abundant in muscle. In insulin-resistant states in mechanisms by which IRS-2 can foster islet hyperplasia rodents and humans, IRS-1 and IRS-2 are differentially could have implications for therapeutic approaches to regulated in different tissues and the relative importance augment islet mass either in vivo or ex vivo in combinaof each IRS (including also IRS-3, IRS-4, Gab1, etc.) for tion with islet transplantation. The parallels between the specific actions of insulin in a given tissue is currently IRS-2 knockout mice and Type 2 diabetes in humans under investigation.
raises the tantalizing question as to whether human diaPancreatic ␤ Cell Compensation Distinguishes betes is caused by mutations in the IRS-2 gene. Disap-IRS-1 from IRS-2 Knockouts pointingly, studies in press in several populations includThe reduction in pancreatic ␤ cell mass even in neonatal ing Danish Caucasians (Bernal et al., 1998) reveal no IRS-2 knockout mice and the inability to increase ␤ cell association between polymorphisms in the IRS-2 gene mass in the face of insulin resistance are critical to the and Type 2 diabetes. development of diabetes. In contrast, the capacity for Do All Paths Lead to the Same Syndrome? ␤ cell hyperplasia in IRS-1 knockout mice most likely
The Insulin Receptor. While complete absence of the protects them against frank diabetes. In the early stages insulin receptor results in severe metabolic abnormaliof the development of diabetes in the IRS-2 knockout ties and neonatal death in humans and rodents, mice mice, glucose-stimulated insulin release in vivo is norwith 50% reduction of insulin receptors due to one null mal. Subsequently, the impact of the failure of normal allele compensate by hypersecreting insulin, resulting ␤ cell expansion postweaning becomes manifest, hyperin normal glucose tolerance (Accili, 1997). Overexpresglycemia progresses, and insulin release is attenuated.
sion of normal insulin receptors in skeletal muscle, the This sequence is reminiscent of Type 2 diabetes in humajor site of insulin-mediated glucose uptake, has a mans and may result, at least in part, from "glucose relatively mild effect to increase insulin sensitivity and toxicity" or glucose-induced desensitization, the pheexpression of a kinase-deficient receptor mutant results nomenon by which increased metabolites of the hexin only mild insulin resistance without diabetes (reosamine biosynthetic pathway abrogate glucose sensviewed in Patti and Kahn, 1996) . These data are consising/insulin secretion in ␤ cells as well as insulin action tent with the "spare receptor" concept reflecting the in muscle and fat (McClain and Crook, 1996; DeFronzo, fact that activation of the full cohort of insulin receptors 1997). This propels a vicious cycle, further aggravating is not required for normal insulin action. In humans, a hyperglycemia. The presence of IRS-2 in pancreatic number of mutations in the insulin receptor have been ductal epithelium, the site of neogenesis of islets from described and the phenotypes range from mild glucose ductal precursor cells, in normal mice and the reduced intolerance to severe diabetes (Kahn et al., 1996) . Such islet mass and failure to undergo hyperplasia in IRS-2 mutations constitute a very rare cause of Type 2 dianull mice (Withers et al., 1998) suggest potentially a betes. more direct role for IRS-2-dependent signaling in the Glucose Transporters. Genetic manipulation of GLUT4, regulation of islet cell replication, neogenesis and/or a more distal (Figure 1 ) but major mediator of insulin apoptosis.
action on glucose transport in muscle and fat, results Implications for Human Diabetes in relatively dramatic phenotypes. Overexpression of Diabetes in the IRS-2 knockout mouse provides a mono-GLUT4 in muscle and/or adipose tissue in transgenic genic mechanism for the long-standing observation that mice results in fasting hypoglycemia, enhanced glucose overt Type 2 diabetes occurs when insulin secretory tolerance, and increased insulin sensitivity (reviewed in capacity can not adequately compensate for impair- Katz et al., 1996) . GLUT4 overexpression has a therapeuments in insulin action (DeFronzo, 1997) . In humans, this tic effect to improve glucose homeostasis and insulin phenomenon is illustrated by the fact that obesity is a sensitivity in genetically obese, diabetic db/db mice or major risk factor for Type 2 diabetes. Whereas obesity mice rendered insulin resistant by high fat feeding or is invariably associated with insulin resistance, most frankly diabetic by injection of the ␤ cell toxin streptozotocin. In the db/db and high fat fed models, increased obese people are not diabetic due to their capacity to GLUT4 overcomes multiple defects in insulin signaltransgenic mice overexpressing normal insulin in the liver. These mice are hyperinsulinemic and show an ageing. Hence, if gene therapy were more feasible for humans, GLUT4 would be a promising target. Interestingly, related reduction in insulin receptor expression, glucose intolerance, and hyperlipidemia without any primary dethe same phenotype is not seen with overexpression of GLUT1, which results in fasting hypoglycemia but fects in insulin action or secretion (reviewed in Patti and Kahn, 1996) . Interestingly, in insulin-resistant, normoglyresistance to insulin stimulated glucose uptake. This most likely results from constitutively high glucose flux cemic mice with one disrupted GLUT4 allele, insulin action is impaired in muscle but not in liver. It will be through the hexosamine biosynthetic pathway (glucose toxicity hypothesis). Thus, increasing glucose transport important to determine whether hepatic insulin resistance develops as these mice become more severely by any mechanism does not necessarily enhance insulin sensitivity.
hyperinsulinemic and hyperglycemic. Importance of Genetic Background Mice that are heterozygous for a null allelle for GLUT4 are normal at birth but males develop progressive hyperMice with combined heterozygous deficiencies in the insulin receptor and IRS-1 genes were created to recainsulinemia and Ͼ50% become overtly diabetic by 4-5 months (Stenbit et al., 1997) . Thus, a relatively mild depitulate the polygenic nature of Type 2 diabetes (Brü ning et al., 1997). While mice heterozygous for either defect fect can initiate a sequence of events that eventuates in Type 2 diabetes in midlife, similar to the progresalone have subclinical phenotypes, the double heterozygotes are highly insulin-resistant and 40% develop Type sion in humans. Interestingly, homozygous disruption of GLUT4 results in growth retardation, severe reduction 2 diabetes at 4-6 months of age despite massive hyperinsulinemia and pancreatic ␤ cell hyperplasia. The fact in adipose tissue, cardiac hypertrophy and failure, but not diabetes (Katz et al., 1996) . Multiple alterations in that the highest insulin levels and greatest ␤ cell hyperplasia occur among the mice that develop overt diabetes organ function and fuel availability and metabolism are evident, and delineation of the molecular physiology will indicates that in this model, even exuberant ␤ cell compensation for insulin resistance is inadequate in some be possible with tissue-specific reconstitution as well as tissue-specific GLUT4 knockout using the Cre recommice. But what about the other 60% of mice that do not develop diabetes despite the same genetic defects? binase loxP system, ideally with inducible promoters in transgenic mice.
Most likely the "clinical" impact of these defects is modified by other genetic factors, especially since these p21 ras . Overexpression of the low molecular weight GTP binding protein, p21
ras driven by an adipose-specific proknockout experiments are performed in outbred populations. moter/enhancer in transgenic mice results in reduced adipose mass and increased insulin sensitivity (HouseThe importance of genetic background has clearly been demonstrated by feeding different strains of mice knecht et al., 1996) . Studies in isolated adipocytes from transgenic mice indicate that this may be mediated by high fat diets. The strains respond with widely varying degrees of hyperinsulinemia and only some develop increased translocation of GLUT4 to the cell surface. However, other in vitro evidence indicates that blocking overt diabetes (Surwit et al., 1991) . Backcrossing indicates that insulin resistance in these mice is determined ras activation does not impair insulin action on glucose transport (Holman and Kasuga, 1997) . Importantly, this by a dominant gene whereas hyperglycemia (i.e., failure of ␤ cell compensation) is determined by a recessive transgenic model illustrates that even when manipulation of a signaling pathway mimics insulin's effects, one gene. Similarly, the severity of diabetes in mice with mutations in genes encoding leptin (ob) or the leptin cannot conclude that this pathway is critical for the normal action of insulin on glucose homeostasis. Prelimreceptor (db) is significantly altered by genetic background. When ob or db is expressed on the C57BL/Ks inary data indicate that such models will provide important insights into the cross-talk between signal transbackground, severe diabetes occurs in association with ␤ cell atrophy (Coleman, 1978) . The same mutations on duction pathways. PEPCK. Overexpression of PEPCK, the rate limiting enthe C57BL/6 background result in obesity and extreme insulin resistance but only mild hyperglycemia because zyme in gluconeogenesis, in transgenic mice targets insulin action in liver (Valera et al., 1994) . The conse-␤ cell hyperplasia and hypertrophy occur. Positional cloning studies are aimed at determining the gene(s) quences are seen in all insulin target tissues and resemble the constellation of defects in Type 2 diabetes. Mice responsible for differences in ␤ cell neogenesis, hypertropy, and/or apoptosis in these strains. overexpressing PEPCK have increased hepatic glucose production and hepatic insulin resistance resulting in In humans, it is possible that defined genetic variations, for example in insulin signaling molecules, may hyperglycemia and hyperinsulinemia. Secondarily, expression of the GLUT4 glucose transporter is downbe modified by constellations of other genes, accounting for the complex inheritance patterns of Type 2 diaberegulated in skeletal muscle causing resistance to insulin action on glucose uptake. Such models indicate that tes. For example, the IRS-1 gene is highly polymorphic with coding sequence variations in ‫%5ف‬ of normal peowhether insulin resistance originates in liver, muscle, or fat, eventually all insulin target tissues may be affected.
ple and in 10%-20% of subjects with Type 2 diabetes (Kahn et al., 1996) . Furthermore, decreased levels of This may be mediated in part by the compensatory hyperinsulinemia itself that down-regulates insulin recepboth the insulin receptor and IRS-1 are seen in insulin target tissues of humans and rodents with Type 2 diabetors and desensitizes postreceptor pathways (Patti and Kahn, 1996) , and by associated metabolic derangetes. The impact of these polymorphisms or reduced expression of signaling molecules could be modified by ments such as elevated plasma free fatty acids (DeFronzo, 1997 In humans the ability of environmental stress to modify "stress test" for the ␤ cell results in gestational diabetes Houseknecht, K.L., Zhu, A.X., Gnudi, L., Hamann, A., Zierath, J.R., in 3%-5% of pregnancies in the Western world and Tozzo, E., Flier, J.S., and Kahn, B.B. (1996) . J. Biol. Chem. 271, resolves within 48 hr of delivery in Ն90% of cases. Thus, 11347-11355. genetic predisposition for limited ␤ cell reserve is unKahn, C.R., Vicent, D., and Doria, A. (1996) . Annu. Rev. Med. 47, masked by pregnancy. Although gestational diabetes is reversible in the short-term, Ն50% of these women will in insulin action are yet to be discovered, and/or (3) the focus for identification of candidate genes has been on the wrong site, i.e., the primary defect leading to insulin resistance may not be in classic insulin target tissues. Generation of signals or biochemical molecules that predispose to diabetes may originate in the brain; a likely example is insulin resistance in the db/db (leptin receptor mutant) mouse. Efforts to identify diabetogenes are now taking a broader focus extending to secretory products of adipocytes (leptin, TNF) and neuropeptides. Thorough testing for concurrent mutations in several candidate genes, albeit a major undertaking, could pay off, expecially when paired with specific biochemical or physiologic subphenotypes. Transgenic models in which one or more candidate genes are manipulated either singly or in combination will continue to be a valuable approach to identifying new susceptibility loci,
